Kalaris Therapeutics Q1 2026 Earnings NarrowerThanExpected Loss Highlights Cost Discipline Amid PreRevenue Biotech INLX Q1 2026 Earnings Significant EPS Miss but Stock Rallies 586 KALV Q1 2026 Earnings Narrower Loss Beats Expectations Clinical Pipeline Progress Underway C4 Therapeutics Q1 2026 Earnings Strong EPS Beat Highlights Cost Discipline Amid PreRevenue Stage GEOS Q1 2026 Earnings Loss Per Share of 086 Reflects Challenging Oilfield Conditions U Q1 2026 Earnings NarrowerThanExpected Loss Drives Shares Higher